107,786 Shares in Roivant Sciences Ltd. $ROIV Purchased by Great Lakes Advisors LLC

Great Lakes Advisors LLC purchased a new position in Roivant Sciences Ltd. (NASDAQ:ROIV) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 107,786 shares of the company’s stock, valued at approximately $3,815,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. SBI Securities Co. Ltd. boosted its position in shares of Roivant Sciences by 1,740.3% during the 4th quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock valued at $27,000 after purchasing an additional 1,166 shares in the last quarter. Allworth Financial LP boosted its position in shares of Roivant Sciences by 48.1% in the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after buying an additional 583 shares during the period. Parallel Advisors LLC boosted its position in Roivant Sciences by 33.7% during the 1st quarter. Parallel Advisors LLC now owns 2,065 shares of the company’s stock worth $57,000 after acquiring an additional 520 shares during the period. Kestra Advisory Services LLC acquired a new stake in Roivant Sciences during the 4th quarter worth about $47,000. Finally, Bessemer Group Inc. grew its stake in Roivant Sciences by 21.8% during the 1st quarter. Bessemer Group Inc. now owns 2,465 shares of the company’s stock valued at $69,000 after acquiring an additional 441 shares in the last quarter. 64.76% of the stock is owned by institutional investors and hedge funds.

Roivant Sciences Price Performance

Shares of ROIV stock opened at $36.84 on Friday. Roivant Sciences Ltd. has a fifty-two week low of $11.54 and a fifty-two week high of $37.97. The stock’s 50-day moving average is $34.48 and its two-hundred day moving average is $30.38. The firm has a market cap of $26.61 billion, a P/E ratio of -69.51 and a beta of 1.12.

Roivant Sciences (NASDAQ:ROIV) last announced its quarterly earnings results on Friday, August 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.04. The business had revenue of $1.44 million during the quarter, compared to analyst estimates of $2.06 million. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%. As a group, research analysts expect that Roivant Sciences Ltd. will post -2 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on ROIV. HC Wainwright upped their target price on Roivant Sciences from $34.00 to $41.00 and gave the company a “buy” rating in a report on Friday, August 7th. Citigroup boosted their price objective on shares of Roivant Sciences from $42.00 to $46.00 and gave the company a “buy” rating in a research report on Monday, August 10th. TD Cowen reiterated a “buy” rating on shares of Roivant Sciences in a research note on Thursday, August 6th. Piper Sandler reiterated an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, May 21st. Finally, Leerink Partners set a $42.00 target price on shares of Roivant Sciences in a research note on Thursday, May 21st. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Roivant Sciences currently has an average rating of “Moderate Buy” and an average price target of $35.14.

Insider Buying and Selling at Roivant Sciences

In other Roivant Sciences news, insider Mayukh Sukhatme sold 284,707 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $36.25, for a total value of $10,320,628.75. Following the completion of the sale, the insider directly owned 18,630,739 shares of the company’s stock, valued at $675,364,288.75. The trade was a 1.51% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Eric Venker sold 200,000 shares of the stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $33.16, for a total transaction of $6,632,000.00. Following the transaction, the chief executive officer owned 1,613,063 shares in the company, valued at approximately $53,489,169.08. This trade represents a 11.03% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 2,520,739 shares of company stock worth $87,746,445 in the last ninety days. Insiders own 8.80% of the company’s stock.

Roivant Sciences Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.